Table 2.

Impact of clinical, hematological factors and prognostic score on clinical outcomes in recurrence or metastatic head and neck cancer patients treated with nivolumab.

Variables	N	Progression-free survival						Overall survival
		Univariate			Multivariate			Univariate			Multivariate
		HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value	HR	95% CI	p-value
ECOG PS
0, 1	102	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
2, 3	24	1.90	1.18–3.06	0.008	2.17	1.30–3.63	0.003	3.14	1.77–5.57	< 0.001	2.94	1.55–5.55	< 0.001
IrAE
Without	85	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
With	41	0.55	0.36–0.84	0.006	0.52	0.34–0.80	0.003	0.49	0.27–0.87	0.016	0.47	0.26–0.86	0.015
Modified Glasgow Prognostic Score
0	70	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
1, 2	47	2.02	1.34–3.03	< 0.001	2.37	1.55–3.63	< 0.001	2.40	1.41–4.10	0.001	2.51	1.45–4.35	< 0.001
Relative eosinophil count
< 1.5	71	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
≥ 1.5	53	0.68	0.46–1.00	0.049	0.68	0.46–1.00	0.048	0.51	0.31–0.86	0.011	0.49	0.29–0.83	0.008
Neutrophil/lymphocyte ratio
< 5	71	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
≥ 5	53	1.28	0.87–1.88	0.218	1.32	0.89–1.95	0.167	1.54	0.93–2.56	0.094	1.56	0.92–2.65	0.096
Platelet/lymphocyte ratio
< 253	62	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
≧ 253	63	1.04	0.71–1.53	0.830	1.10	0.75–1.63	0.626	1.37	0.82–2.29	0.236	1.37	0.80–2.35	0.246
Best overall response
SD, PD	97	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
CR, PR	29	0.19	0.11–0.33	< 0.001	0.17	0.10–0.30	< 0.001	0.18	0.08–0.41	< 0.001	0.18	0.07–0.42	< 0.001
Prognostic score
0–1	27	1.00	–	–	1.00	–	–	1.00	–	–	1.00	–	–
2–3	61	2.78	1.60–4.83	< 0.001	3.44	1.95–6.06	< 0.001	6.67	2.04–21.90	< 0.001	7.63	2.29–25.37	< 0.001
4–5	28	6.11	3.22–11.61	< 0.001	7.77	3.98–15.15	< 0.001	15.06	4.43–51.13	< 0.001	14.66	4.28–50.22	< 0.001
		Ptrend < 0.001			Ptrend < 0.001			Ptrend < 0.001			Ptrend < 0.001

Adjusted for age, sex, primary tumor site, platinum sensitivity, and site of recurrence.

ECOG PS Eastern Cooperative Oncology Group Performance Status, irAE immune-related adverse events.